:::::::USA Set to Reschedule Cannabis::::::: HHS Releases Recommendation Documents:::::::

[pipeline]

Not really excited at the prospect of FDA regulating medical cannabis if it gets moved to Schedule 3 status. Maybe they will follow the guidelines they decide with CBD. They want to have discussions with lawmakers. Good sign. Maybe they can do the Medical cannabis regulations at the same time for all the adult-use markets around the nation!

FDA Official Says Agency Is ‘Actively’ Exploring CBD Regulations As It Continues To Monitor Kratom

The Food and Drug Administration (FDA) is “actively” exploring a potential regulatory framework for CBD, with plans to prioritize the issue in the next year, a top official says. Meanwhile, the agency is also investigating issues related to kratom. FDA Deputy Commissioner for Policy...

www.marijuanamoment.net

 

[pipeline]

Having adult- use cannabis in Virginia would be good news because Washington DC is on the border of Virginia.

Virginia Marijuana Sales Legislation Clears House And Senate In Identical Form, One Step Away From Governor’s Desk

The Virginia House of Delegates and Senate approved identical versions of legislation to legalize retail cannabis sales on Wednesday, putting the reform one procedural step away from the governor’s desk—actions that come a day after a committee’s amendments had threatened to upend bicameral...

www.marijuanamoment.net

 

[pipeline]

Didn't all this just happen in the Regan, Bush, and Clinton era in the continuation of the war on drugs? There were studies done by the government or on government research grants, which reached certain conclusions that were later found to be wrong.

So once these studies are done on cannabis, is the government(s) going to say we have all the answers now? At the same time they'd be ignoring the scientific consensus of peer reviewed research in the USA as well as around the world. There is also the ancient history of medical uses that backs it up.

Look at all the people benefiting from it in the legal states.

What made me think about this is psilocybin is becoming legal to use with little hesitation compared with cannabis. Its surprising because of the prevalence of cannabis.

Recent polling suggests about 1 in 6 people claim to currently use cannabis.

 

[pipeline]

The Mystery of Marijuana: Science and the U.S. War on Drugs - PMC

www.ncbi.nlm.nih.gov

The Mystery of Marijuana: Science and the U.S. War on Drugs​

Philippe Bourgois

The mystery of why marijuana is so severely repressed by law enforcement should be especially humbling for public health researchers in the United States and for the field of science studies more broadly. It demonstrates the need for putting institutional power politics and the social construction of reality into the center of our analysis of drugs. It also drills home the naiveté of assuming that “objective scientific evidence” shapes drug policy, media coverage, and popular opinions and values. Despite repeated documentation of the much lower risks associated with marijuana consumption compared to alcohol use, U.S. federal law enforcement agencies in the 2000s have been spending over $4 billion a year arresting almost three quarters of a million people on marijuana charges—usually merely on charges of possession (Schlosser, 2003).

Public health researchers need to develop theoretical and practical strategies to explore the social meaning of drugs and the impact of power politics on health. “Rigorous” technical statistics on drug consumption and health risks are meaningless in a vacuum. It has not been enough to measure the spread of infectious diseases or the prevalence of risky practices. We need to examine the larger power relations that drive health, policy, and cultural values. The repression of marijuana illustrates this well. The widespread prevalence of recreational marijuana consumption among youth continues to generate an irrational moral panic akin to the cold war anti-communist crusade of the 1950s despite all evidence that marijuana causes few significant health or behavioral threats to the vast majority of the people who consume it.

This is not to say that marijuana is harmless to everyone. The pharmacological properties of a drug are not the sole determinants of its potential harm. Of special importance and concern is the nexus between socially structured vulnerability and destructive drug consumption (Bourgois, 2003a)—especially in a country like the United States where a punitive social service infrastructure exacerbates the suffering of the poor. For example, when I was conducting fieldwork among crack dealers who had grown up in dire poverty in East Harlem (Bourgois, 2003b), I collected accounts from them of how, as teenagers, they had fished “roaches [butts of marijuana cigarettes]” out of puddles of urine in the stairways of their housing projects to dry them and smoke them. Most middle-class users cannot conceive of such a desperate pursuit of the marijuana high.

Despite (or perhaps because of) law enforcement’s efforts, hip-hop culture defiantly celebrates marijuana and this probably represents a public health boon. During the 1950s through the 1970s heroin was “cool” among disenfranchised urban youth and among trend setters in the underground economy (Finestone, 1957). In the early to mid-1980s crack/cocaine had become the drug of choice (Golub and Johnson 1999). By the 2000s, however, most chronic crack smokers were over 30 and most heroin injectors were over 40 (Bourgois and Schonberg, in press). Inner city youth shunned injection drug use and the expression “are you on crack!” had become a comic insult on elementary school playgrounds. In future decades we may consider the popularity among poor urban youth of “blunts” [marijuana rolled in cigar papers] to have been a lucky historical accident (as well as testimony to popular common sense).

From a risk reduction perspective, it is important that we take seriously the possibility that the increase in marijuana use has been reducing alcohol and narcotic drug consumption. Sadly, the greatest harm caused by marijuana comes from the collateral damage of its illegality. Criminalization has dramatically increased the profitability of marijuana and the violence surrounding its trafficking. Furthermore, millions of vulnerable lives are ruined as large sectors of poorly educated, destitute youth serve prison terms for selling trivial amounts of marijuana. Prison records block access to legal employment and draconian enforcement of parole violation statutes around recreational marijuana use spin the revolving doors of the correctional system. In California, for example, tens of thousands of young men are routinely reincarcerated each year by their parole officers without appearing before a judge (State of California Little Hoover Commission 2003) solely for “dirty urines,” that is, a trace of marijuana found during a random urine test.

The War on Drugs has clearly backfired in the United States. In 2007 both marijuana and heroin are now more potent and easier to buy than ever before (Ciccarone, Krauss and Unick 2007; Office of National Drug Control Policy, 2000). In contrast, the decriminalization of marijuana that has occurred in Holland since the 1970s and that currently exists, de facto, in several other European countries, such as Switzerland (and in certain North American municipalities) increases the possibility of regulating marijuana and of providing treatment for those individuals who become problem users.

The U.S. federal government’s zero-tolerance approach to marijuana is only the tip of the iceberg of misguided punitive policy that exacerbates the negative health effects of drug use across the globe. A righteous, opposition to the principle of harm reduction is deeply rooted in U.S. history and culture. Politicians prove their patriotism by calling for war instead of for public health services. Needle exchange, for example, has still not been legalized at the national level in the United States out of a fear that it “condones drug use.” In the first half of the 2000s U.S. diplomats invested more energy than ever in actively combating risk reduction initiatives such as treatment of heroin addicts through opiate prescription programs or supervised injection facilities for out-of-treatment uses (Editor 2003). The United States is the principle funder of drug research and of drug control—as well as of military aid. It is the most politically, militarily, and economically powerful nation and does not hesitate to pressure friends and foes to obey its value-laden dictates on drug control even when they fly in the face of the scientific evidence collected by public health researchers.

 

[pipeline]

So the government has legalized taking bribe money. These business lobby groups heavily influence lawmakers. A representative from the Indiana Chamber of Commerce testified at a committee hearing for a cannabis bill last year, and they said they needed more research to be done before they would be able to agree to legalized medical cannabis.

The insurance companies are what are telling these businesses to vote this way in the chamber of commerce. So the real power structure is becoming visible. The ones who have the most representation and power in the lawmaking process are big banks who own insurance companies. They dictate to the busness owners how they are going to hire manage employees. The businesses then have to vote that way in the Board of the Chamber of commerce. Then the Chamber of Commerce works to lobby lawmakers to get policies which align which the insurance companies.

The lamakers respond to the advice of the big business lobby groups and ignore the will of the people.

Liberty, natural medicine and the welfare of the people are lost, and they are straight going for the money.

Indiana Chamber Foundation Funds Vital Policy Research

The Indiana Chamber Foundation funds practical policy research, initiates actions and seeks solutions that positively impact Indiana’s economic future.

www.indianachamber.com

 

[Sweatloaf]

And 8 out of 10 people in the U.S. have a cannabis dispensary of some sort in their county that they live in. We're coming to a crossroads in the not too distant future: Either the federal government will "get with the times" in relation to the majority of the will of the people or it will have to admit to being against the will of the people and act in an autocratic and authoritarian manner that's officially counter to what the people want in governance. We're not there yet. There's always been the façade that the government is on the side of the people and working for the people. There's no way that kind of appearance can continue after a certain point.

 

[Unca Walt]

Medical Marijuana Growers And Caregivers Can Own Guns, But Patients Can’t, FBI Says In Little-Noticed Memo

Being a state-registered medical marijuana caregiver or grower doesn’t automatically disqualify a person from owning a firearm, the FBI says. But merely possessing a medical cannabis card as a patient does render a person ineligible. Amid the growing tension between federal gun policies and the...

www.marijuanamoment.net

NOTICE TO ALL:

This is the vicious crap the VA stands for. Sure, you can have a card... No problem. Got one? Fine. We will be at your house to search it for guns this afternoon.

Not a fukking joke, pilgrims. There are vets who received this treatment. I do not have a card because I am a veteran... and found out about what happens to vets with cards before I made that mistake.

 

[pipeline]

This has been a big waste of taxpayer dollars and legislative energy, going through the lawmaking process in every state.

Its still a long way off before federal legalization will ever take place. In my opinion when the DEA finally makes their ruling by early 2025 then it will still be another 2-5 years for the FDA to meet with lawmakers and develop a proper regulatory structure. The FDA spokes person spoke about Hemp regarding the regulations.

Virginia GOP Governor Still Doesn’t Have ‘Any Interest’ In Signing Marijuana Sales Bill As Democratic Legislature Approves Plan

A day after the Virginia legislature sent a retail marijuana sales bill to Gov. Glenn Youngkin (R), a spokesperson in his office told Marijuana Moment that there’s no new update on the governor’s stance on the issue, instead citing earlier comments in which he said he doesn’t “have any interest...

www.marijuanamoment.net

 

[pipeline]

Hemp Industry Pushes Congress To Hold FDA Accountable With Hearing On CBD Regulation Inaction

A coalition of hemp industry organizations are calling on a House committee to hold a hearing addressing the ongoing lack of Food and Drug Administration (FDA) regulations for products made with constituents of the crop such as CBD. In a letter addressed to House Energy and Commerce Committee...

www.marijuanamoment.net

 

[pipeline]

And 8 out of 10 people in the U.S. have a cannabis dispensary of some sort in their county that they live in. We're coming to a crossroads in the not too distant future: Either the federal government will "get with the times" in relation to the majority of the will of the people or it will have to admit to being against the will of the people and act in an autocratic and authoritarian manner that's officially counter to what the people want in governance. We're not there yet. There's always been the façade that the government is on the side of the people and working for the people. There's no way that kind of appearance can continue after a certain point.

Thats what I'm saying, its adding to the politically tense election year. They are setting a pressure cooker for another Jan 6. 2021 situation where they frame supporters of personal liberty and the US Constitution as violent domestic extremists.

Its a strategy to take us out using terrorism laws crated with the Patriot act to taget islamic extremism. Now its being used against us.

 

[pipeline]

FDA Official Says Agency Is ‘Actively’ Exploring CBD Regulations As It Continues To Monitor Kratom

The Food and Drug Administration (FDA) is “actively” exploring a potential regulatory framework for CBD, with plans to prioritize the issue in the next year, a top official says. Meanwhile, the agency is also investigating issues related to kratom. FDA Deputy Commissioner for Policy...

www.marijuanamoment.net

FDA Official Says Agency Is ‘Actively’ Exploring CBD Regulations As It Continues To Monitor Kratom​

Published
4 seconds ago
on
February 28, 2024
By
Kyle Jaeger

The Food and Drug Administration (FDA) is “actively” exploring a potential regulatory framework for CBD, with plans to prioritize the issue in the next year, a top official says. Meanwhile, the agency is also investigating issues related to kratom.

FDA Deputy Commissioner for Policy, Legislation, and International Affairs Kimberlee Trzeciak discussed the agency’s cannabis and kratom interests during a webinar hosted by the Alliance for a Strong FDA this month.

Asked about issues that are “top of mind” for the agency in 2024 and where officials hope to engage with Congress, Trzeciak said that later this year or next year FDA wants to address setting up “an appropriate regulatory framework for CBD.”


Later in the conversation, the FDA official was asked specifically about how the agency is “prioritizing” its work on cannabis and kratom regulations, and she said officials are taking a number of factors into consideration as they work to address the substances.

“In almost every neighborhood you go to, you can see stores on the corners that are marketing CBD and kratom and others,” she said. “And one of the things that we have been thinking through here at FDA, using CBD as an example, is what does the regulatory framework for those products look like?”


“Based on what we know about CBD in particular, we do not think that those products would be able to meet the safety standards that we have in place for foods and dietary supplements today,” she said, referencing the agency’s position after it declined to enact regulations for the non-intoxicating cannabinoid that was legalized under the 2018 Farm Bill.

“What can we do in terms of regulatory tools to ensure that this product is going to be marketed that consumers are clearly aware of what the product is, what is in it and making sure that we have basic information about the marketplace?” Trzeciak said. “I like to think of it as the common regulatory tool that we have across the other products that we regulate.”


She added that FDA wants to “work with Congress on this effort,” including possible rulemaking around CBD product labeling and packaging.

“For example, how can we ensure that the agency knows if there are adverse events that are being reported, so we can identify those trends, making sure that the product is being manufactured or produced in a way that’s safe and quality?” she said.

Kratom reform advocates say the deputy commissioner’s comments represent a “shift” in the agency’s policy perspective on the issue. Historically, FDA hasn’t engaged in the kratom debate as actively as other agencies such as the National Institute on Drug Abuse (NIDA).

FDA Deputy Commissioner Signals Shift in FDA Policy on #Kratom and #CBD Regulation.
new FDA study finds “kratom appears to be well tolerated at all dose levels.”
Read & download full doc https://t.co/mZltcHFxv7 pic.twitter.com/AN3UpH7IR7
— American Kratom Association (@TheKratomAssn) February 27, 2024

Meanwhile, FDA has faced criticism from hemp stakeholders and lawmakers over its prior decision not to regulate CBD, despite its prevalence in the marketplace. But it’s insisted that it will need additional congressional authorization in order to develop such regulations.

In a recent letter addressed to House Energy and Commerce Committee leaders, 28 state and national nonprofits focused on hemp and dietary supplements said that “the time for a hearing has never been riper” to examine regulatory pathways that FDA could enact to allow for the lawful marketing of hemp products for humans and animals.


The committee responded to FDA’s inaction last summer by putting out a Request for Information (RIF) from experts on the best path forward for regulating hemp, with hundreds of respondents sharing their perspective and recommendations.

With respect to congressional action, Sens. Ron Wyden (D-OR), Rand Paul (R-KY) and Jeff Merkley (D-OR), along with Rep. Earl Blumenauer (D-OR), filed legislation last July that would remove regulatory barriers that FDA claims prevents it from allowing the hemp marketing.

The House Oversight and Accountability Subcommittee on Health Care and Financial Services also held a hearing on FDA inaction over CBD last year, a first-of-its-kind meeting where bipartisan members strongly criticized the agency’s position.


Meanwhile, the National Association of State Departments of Agriculture (NASDA) is separately calling on Congress to increase the THC limit for legal hemp as one of their 2024 policy priorities.

The 0.3 percent THC limit for hemp that was imposed under the 2018 Farm Bill that federally legalized the crop has long been subject to criticism from stakeholders and lawmakers across the aisle. And one Justice Department researcher recently called into question the rationale for the restriction, suggesting it was arbitrarily decided based on a 1950s-era article that was adopted into federal statute.


The Congressional Research Service (CRS) recently outlined how differing policy priorities among industry stakeholders could complicate the task of updating the next farm bill’s hemp provisions, but there are several areas of agreement within the top industry groups.

One of those shared interests is amending the law to raise the THC limit to one percent for compliant hemp—a proposal that was also addressed in a standalone bill from Rep. Chellie Pingree (D-ME) in 2022.

It’s unclear if congressional lawmakers will ultimately tackle the Farm Bill this year. The 2018 version was set to expire at the end of last year, but it was extended under a bill President Joe Biden signed.

Meanwhile, FDA has also been engaged in other drug policy reform debates amid an ongoing federal review into marijuana scheduling, which prompted the agency to recommend. moving cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA).


FDA recently highlighted its scientific review into marijuana—a process that involved a comprehensive analysis of research, as well looking at hundreds of posts on social media platforms to see how consumers described cannabis’s therapeutic impact.

Earlier this month, FDA officials also joined scientists at a public meeting on next steps for conducting research to develop psychedelic medicines.

The meeting came months after FDA issued historic draft guidance on psychedelics studies, providing scientists with a framework to carry out research that could lead to the development of novel medicines.

To that end, FDA also recently accepted an application to review MDMA-assisted therapy as treatment option for post-traumatic stress disorder (PTSD), agreeing to carry out the analysis on an expedited basis.

 

[pipeline]

Thanks Gypsy! Keep fighting the good fight, guys!

God with us!

 

[pipeline]

Hawaii Senate Panels Approve Marijuana Legalization Bill, Sending It To Floor Vote Expected Next Week

A pair of Senate committees in Hawaii has advanced a bill that would legalize marijuana in the state, adopting a number of amendments to the underlying proposal before sending it to the chamber floor where a vote is expected next week. Last year the Senate passed a separate legalization bill...

www.marijuanamoment.net

 

[pipeline]

Congressional Leaders’ Bill Extends State Medical Marijuana Protections And Calls For Studying Legalization Models

Bicameral congressional leaders have released a spending package that contains a number of marijuana-related items—including bill provisions preserving protections for state medical cannabis programs and report language that calls for the federal government to study state legalization laws and...

www.marijuanamoment.net

 

[pipeline]

GOP Senators Push For Federal And State Response To Indian Tribe’s 4/20 Marijuana Sales Plan In North Carolina

Two Republican senators are asking federal, state and local officials what steps they are taking to enforce marijuana prohibition as an Indian tribe prepares to launch recreational cannabis sales on its lands within North Carolina on April 20. On Friday, Sens. Thom Tillis (R-NC) and Ted Budd...

www.marijuanamoment.net

 

[pipeline]

Hawaii Senate Passes Marijuana Legalization Bill

Hawaii’s Senate has passed legislation to legalize and regulate adult-use marijuana in the state, sending the proposal next to the House of Representatives. The legislation, SB 3335, would allow adults 21 and older to possess up to an ounce of marijuana and up to five grams of cannabis...

www.marijuanamoment.net

Going to be awesome to have legal cannabis for sale in Hawaii.

But.... What is this absolute nonsense about NO HOME GROW? How is that a good idea to allow cannabis possession for small amounts, licensed sales, but no home growing? Do they think people are going to not grow it? Cannabis grows very easily like a weed.

Politicians are being bribed by lobbyist for the prison industry, looks like to me.

Just making criminals out of everyday people trying to provide medicine for their family. This is a dangerous time, guys!

 

[pipeline]

UN Body Reaffirms That Marijuana Legalization Violates International Treaties, While Addressing Germany Cannabis Reform And U.S. Psychedelics Movement

The United Nations’s (UN) drug control body is reiterating that it considers legalizing marijuana for non-medical or non-scientific purposes a violation of international treaties, though it also said it appreciates that Germany’s government scaled back its cannabis plan ahead of a recent vote...

www.marijuanamoment.net

​

UN Body Reaffirms That Marijuana Legalization Violates International Treaties, While Addressing Germany Cannabis Reform And U.S. Psychedelics Movement​

Published
5 seconds ago
on
March 6, 2024
By
Kyle Jaeger


The United Nations’s (UN) drug control body is reiterating that it considers legalizing marijuana for non-medical or scientific purposes a violation of international treaties, though it also said it appreciates that Germany’s government scaled back its cannabis plan ahead of a recent vote. The global narcotics agency is also taking note of the psychedelics policy reform movement in U.S. states.
This is mostly par for the course for the International Narcotics Control Board (INCB), which has routinely criticized countries for allowing the enactment of cannabis legalization due to their obligations under various Single Convention treaties going back to 1961. But as Germany entered the fold, and the U.S. has continued to move toward marijuana and psychedelics reform, the body is again making its disappointment known.
INCB’s 2023 annual report, which was published on Tuesday, “underscores” that member nations are required to “take such legislative and administrative measures as may be necessary” to criminalize “the production, manufacture, export, import, distribution of, trade in, use and possession of drugs” such as marijuana under decades-old treaty agreements.

“The Board continues to reiterate its concern regarding the legalization of the use of cannabis for non-medical and non-scientific purposes in several jurisdictions, with other jurisdictions considering similar action,” it said.
To that point, INCB also included a recommendation in the latest report to recall an analysis from its 2022 report that, at one point, suggested that the U.S. is out of compliance with drug treaty obligations because the federal government is passively allowing states within the country to legalize marijuana.

“The apparent tension between these provisions and the trend towards legalization must be addressed by the signatories to the three drug control conventions,” it said.

Honoured to launch #INCB's 2023 Annual Report. The thematic chapter highlights opportunities to improve the reach of treatment & prevention services using the Internet & social media, and makes recommendations to address Internet-related drug trafficking. https://t.co/gQIRrmowaN pic.twitter.com/G6mbDLmO6w
— Jallal Toufiq (@INCB_President) March 5, 2024

Meanwhile, the new report also discusses the board’s ongoing monitoring of efforts to legalize marijuana in Germany. The country’s parliament officially approved a bill to legalize cannabis nationwide last month.
“The Board has had ongoing discussions with the authorities in Germany and has taken note of the evolution of the originally planned control measures following concerns expressed by the European Commission, in particular with respect to the provisions on the sale of cannabis in speciality shops to adults for non-medical purposes,” it said.
That’s in reference to changes to the Germany government’s legalization plan that makes it so possession and home cultivation would become legal, while authorizing social clubs to distribute marijuana to members, but not establishing a full-scale commercial market right away.

Overall, while German supporters have said legalization would take effect in April if the legislation is enacted, there are questions about that timeline. The country’s Bundesrat may move to refer the legislation to a mediation committee to address criminal justice-related implications of the law, which could mean several months of additional discussion.
In the U.S., INCB recognized that while “cannabis remains subject to the highest level of control under the Controlled Substances Act, use of the drug has been legalized in several states for non-medical purposes.”

“The Board has repeatedly expressed its concern that these developments may be inconsistent with the country’s legal obligations as a party to the three international drug conventions,” it said.
“The Board continues to maintain a constructive dialogue with the Government of the United States on these matters,” it added.
The report further notes that President Joe Biden’s mass pardons for federal marijuana possession offenses are actively “being implemented” by the Justice Department.
“While the presidential pardon does not expunge the existing conviction, it removes civil or legal restrictions, such as on the rights to vote, hold office or sit on a jury, and lifts barriers to housing, employment and educational opportunities,” it says.
Notably, INCB did not mention the parallel presidential directive that’s underway to review the scheduling status of cannabis under federal law.

The reason that lack of mention stands out is because supporters and opponents of rescheduling under U.S. law, as recommended by the U.S. Department of Health and Human Services (HHS), have made competing arguments about the influence of international treaty obligations in the final decision that the Drug Enforcement Administration (DEA) is expected to hand down.
For example, a Democratic congresswoman recently implored DEA to “reject any argument” that rescheduling marijuana under federal law would constitute a violation of international treaty obligations. She also asked the agency to reveal a list of any “outside partners” it has met with to discuss the global implications of a potential cannabis reclassification.

Legal experts recently released an opinion that disputes that assessment. In fact, they argued that a move to Schedule III would better uphold the country’s broader obligations under international law to regulate cannabis in a way that protects public health and safety.
Among those who’ve raised concerns about treaty obligations blocking a move to Schedule III is Rep. Andy Harris (R-MD), who raised the issue in a letter sent to DEA Administrator Anne Milgram late last month, claiming that any reclassification that puts marijuana outside of Schedule I or Schedule II “would constitute a violation of the Single Convention,” referring to the 1961 United Nations (UN) Single Convention on Narcotic Drugs.
But as a coalition of 12 senators pointed out in a separate letter to Milgram a week earlier, the UN has since revised global cannabis scheduling policies and allowed other member states, such as Canada, to legalize and regulate marijuana without penalty. Those lawmakers urged DEA to legalize marijuana completely.

Additionally, INCB in its new report said that it is monitoring psychedelics policy developments in the U.S. and in other countries, including the legalization of psilocybin services in Oregon and a broader class of psychedelics in Colorado.
“A growing interest in the therapeutical potential of psychedelic drugs and the potential risks in their unregulated use has also been noted,” the report said. “While clinical studies on the use of psychedelics are conducted in some countries, most of the health, wellness and tourism businesses involving the use of psychedelics have been operating without much regulatory oversight. Unsupervised and experimental use of those substances, even in microdoses as self-medication, may put some vulnerable populations at risk.”

 

[pipeline]

Couldn't adult-use legalization be considered medicinal since cannabis is a medicine?

I really don't see where the contradiction exists except in the corrupt minds of the controlling corporate elite in high authority positions.

See, everyone has been trained to think of cannabis as a drug of abuse, therefore, everyone will suffer now because, supposedly, the people are incapable of using cannabis as a medicine without a doctor's guidance. This is not true, due to the favorable safety profile of cannabis. Its a valuable therapeutic that can be used in a wide range of dosages with little adverse or side effects.

Why can't we just say, alright adults are able to purchase or produce cannabis for use as medicine. Then we can go from there allowing people to live dignified lives where they are responsible for using cannabis in a way that is helpful for them.

Liberty or death. Where is the love?

 

[pipeline]

I think this is a move to further desabilize the medical system. Doctors are FDA licensed to sell pharmaceuticals which does have any regulatory framework for natural medicines like cannabis.

Doctors, if they were allowed to prescribe cannabis could be held accountable for prescribing cannabis to too many patients. Maybe this will push the customers of the good doctors to go to teledoc services or other doctors they don't prefer to get the medical cannabis prescription.

I would think cannabis should be placed in the GRASS (generally recognized as safe substances) and have age restrictions in place to prevent minors from purchasing it. That way adults can use cannabis the way that helps them without having to play around finding out the doctor they love won't prescribe it to them.

This is getting silly.... And thats the point. Look over ==================>>>>>>>THERE!!!!

 

[pipeline]

Yeah red face